|
Back to Home » June 2018 News » Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Canc |
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Canc |
June 23, 2018
BOULDER, Colo., June 23, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a...
Source URL: https://www.prnewswire.com/news-releases/array-biopharma-announces-a-62-observed-overall-survival-at-one-year-from-the-phase-3-beacon-crc-safety-lead-in-of-the-combination-of-encorafenib-binimetinib-and-cetuximab-in-braf-mutant-crc-at-the-esmo-20th-world-
|
|
|
|
